Immunology startup raises $157M, plans to expand Seattle footprint
Since its founding in May 2020, immunology startup GentiBio has made major strides, validating its regulatory T-cell-based platform in the lab. Now, with the help of $157 million in new venture capital, it plans to ready its lead candidate for the clinic in early 2022.
GentiBio, whose drug is designed to treat Type 1 diabetes, plans to more than quintuple its headcount, growing in both Seattle and Boston, company officials said.
Although the startup is just over a year old, CEO and co-founder Adel…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Rowan Walrath Source Type: news
More News: Allergy & Immunology | American Health | Diabetes | Diabetes Type 1 | Endocrinology | Health Management | Venture Capital